Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
27 07 2022
Historique:
pubmed: 28 6 2022
medline: 30 7 2022
entrez: 27 6 2022
Statut: ppublish

Résumé

Integration of the reverse-transcribed genome is a critical step of the retroviral life cycle. Strand-transfer inhibitors (INSTIs) used for antiretroviral therapy inhibit integration but can lead to resistance mutations in the integrase gene, the enzyme involved in this reaction. A significant proportion of INSTI treatment failures, particularly those with second-generation INSTIs, show no mutation in the integrase gene. Here, we show that replication of a selected dolutegravir-resistant virus with mutations in the 3'-PPT (polypurine tract) was effective, although no integrated viral DNA was detected, due to the accumulation of unintegrated viral DNA present as 1-LTR circles. Our results show that mutation in the 3'-PPT leads to 1-LTR circles and not linear DNA as classically reported. In conclusion, our data provide a molecular basis to explain a new mechanism of resistance to INSTIs, without mutation of the integrase gene and highlights the importance of unintegrated viral DNA in HIV-1 replication.

Identifiants

pubmed: 35758669
doi: 10.1128/jvi.00676-22
pmc: PMC9327692
doi:

Substances chimiques

DNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0067622

Références

J Virol. 2013 Dec;87(23):12701-20
pubmed: 24049167
Mol Ther. 2011 Mar;19(3):547-56
pubmed: 21157436
Int J Biochem Cell Biol. 2004 Sep;36(9):1752-66
pubmed: 15183342
Retrovirology. 2011 Jul 01;8:52
pubmed: 21722380
Retrovirology. 2016 Jan 05;13:1
pubmed: 26728316
Front Microbiol. 2017 Jan 11;7:2165
pubmed: 28123383
Viruses. 2021 Dec 14;13(12):
pubmed: 34960770
Methods Mol Biol. 2005;304:139-54
pubmed: 16061972
J Virol. 2021 Jun 10;95(13):e0028521
pubmed: 33883218
Science. 2001 Aug 24;293(5534):1503-6
pubmed: 11520990
mBio. 2020 Jun 2;11(3):
pubmed: 32487757
mBio. 2021 Jan 12;12(1):
pubmed: 33436439
EMBO J. 2001 Jun 15;20(12):3272-81
pubmed: 11406603
J Infect Dis. 2018 Nov 5;218(12):2020
pubmed: 30085190
J Virol. 2001 Sep;75(17):7944-55
pubmed: 11483739
Retrovirology. 2015 Mar 12;12:24
pubmed: 25808736
Retrovirology. 2013 Aug 13;10:87
pubmed: 23938039
Science. 2000 Jan 28;287(5453):646-50
pubmed: 10649997
Lancet HIV. 2017 Dec;4(12):e547-e554
pubmed: 29107562
Antimicrob Agents Chemother. 2014 Oct;58(10):6101-10
pubmed: 25092689
Curr Opin Infect Dis. 2013 Feb;26(1):43-9
pubmed: 23242340
J Biol Chem. 1996 Mar 8;271(10):5393-7
pubmed: 8621393
Antimicrob Agents Chemother. 2021 May 18;65(6):
pubmed: 33722887
Lancet HIV. 2015 Apr;2(4):e127-36
pubmed: 26424673
Curr Infect Dis Rep. 2013 Feb;15(1):85-100
pubmed: 23180144
mBio. 2017 Sep 26;8(5):
pubmed: 28951475
J Antimicrob Chemother. 2022 Feb 23;77(3):574-577
pubmed: 34894227

Auteurs

Clémence Richetta (C)

LBPA, ENS Paris-Saclay, CNRS UMR8113, IDA FR3242, Université Paris-Saclay, Cachan, France.

Frédéric Subra (F)

LBPA, ENS Paris-Saclay, CNRS UMR8113, IDA FR3242, Université Paris-Saclay, Cachan, France.

Isabelle Malet (I)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP) AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.

Hervé Leh (H)

LBPA, ENS Paris-Saclay, CNRS UMR8113, IDA FR3242, Université Paris-Saclay, Cachan, France.

Charlotte Charpentier (C)

INSERM, IAME, UMR 1137, Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.

Angela Corona (A)

Department of Life and Environmental Sciences, University of Cagliarigrid.7763.5, Cittadella Universitaria di Monserrato, Monserrato, Italy.

Gilles Collin (G)

INSERM, IAME, UMR 1137, Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.

Diane Descamps (D)

INSERM, IAME, UMR 1137, Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, Paris, France.

Eric Deprez (E)

LBPA, ENS Paris-Saclay, CNRS UMR8113, IDA FR3242, Université Paris-Saclay, Cachan, France.

Vincent Parissi (V)

Fundamental Microbiology and Pathogenicity Laboratory, UMR 5234 CNRS-University of Bordeaux, SFR TransBioMed, Bordeaux Cedex, France.

Vincent Calvez (V)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP) AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.

Enzo Tramontano (E)

Department of Life and Environmental Sciences, University of Cagliarigrid.7763.5, Cittadella Universitaria di Monserrato, Monserrato, Italy.

Anne-Geneviève Marcelin (AG)

Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP) AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, Paris, France.

Olivier Delelis (O)

LBPA, ENS Paris-Saclay, CNRS UMR8113, IDA FR3242, Université Paris-Saclay, Cachan, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH